{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:43:45Z","timestamp":1787064225710,"version":"build-2736575974"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T00:00:00Z","timestamp":1527724800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.01235","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T00:31:04Z","timestamp":1527726664000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["RhoA Drives T-Cell Activation and Encephalitogenic Potential in an Animal Model of Multiple Sclerosis"],"prefix":"10.3389","volume":"9","author":[{"given":"Alba","family":"Manresa-Arraut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flemming Fryd","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cord","family":"Brakebusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohreh","family":"Issazadeh-Navikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hasseldam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,5,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","article-title":"Pathological mechanisms in progressive multiple sclerosis","volume":"14","author":"Mahad","year":"2015","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/brainsci7070078","article-title":"Multiple sclerosis: immunopathology and treatment update","volume":"7","author":"Dargahi","year":"2017","journal-title":"Brain Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.neuro.30.051606.094313","article-title":"Multiple sclerosis: an immune or neurodegenerative disorder?","volume":"31","author":"Trapp","year":"2008","journal-title":"Annu Rev Neurosci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ncl.2010.12.010","article-title":"Epidemiology of multiple sclerosis","volume":"29","author":"Ramagopalan","year":"2011","journal-title":"Neurol Clin"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2010.04143.x","article-title":"T cells in multiple sclerosis and experimental autoimmune encephalomyelitis","volume":"162","author":"Fletcher","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.3892\/etm.2017.4410","article-title":"Multiple sclerosis: pathology, diagnosis and treatments","volume":"13","author":"Huang","year":"2017","journal-title":"Exp Ther Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.msard.2016.11.002","article-title":"Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: a double-blind, randomized controlled trial and open-label pharmacokinetic study","volume":"11","author":"Saida","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"B11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1212\/WNL.0000000000003612","article-title":"Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis","volume":"88","author":"Bargiela","year":"2017","journal-title":"Neurology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0b013e31824e8ee7","article-title":"Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial","volume":"78","author":"Coles","year":"2012","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","article-title":"Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy","volume":"86","author":"Tuohy","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2011.12.003","article-title":"Rho GTPases: masters of T lymphocyte migration and activation","volume":"142","author":"Rougerie","year":"2012","journal-title":"Immunol Lett"},{"key":"B15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1083\/jcb.201002067","article-title":"Coordinated RhoA signaling at the leading edge and uropod is required for T cell transendothelial migration","volume":"190","author":"Heasman","year":"2010","journal-title":"J Cell Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1083\/jcb.200103048","article-title":"RhoA is required for monocyte tail retraction during transendothelial migration","volume":"154","author":"Worthylake","year":"2001","journal-title":"J Cell Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1074-7613(00)80519-1","article-title":"Different functions of the GTPase Rho in prothymocytes and late pre-T cells","volume":"7","author":"Galandrini","year":"1997","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1093\/emboj\/16.9.2397","article-title":"The GTPase Rho has a critical regulatory role in thymus development","volume":"16","author":"Henning","year":"1997","journal-title":"Embo J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1084\/jem.192.1.77","article-title":"The GTPase rho controls a p53-dependent survival checkpoint during thymopoiesis","volume":"192","author":"Costello","year":"2000","journal-title":"J Exp Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri798","article-title":"T-cell development and the CD4-CD8 lineage decision","volume":"2","author":"Germain","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0014-5793(03)00351-X","article-title":"Rho kinase is required for CCR7-mediated polarization and chemotaxis of T lymphocytes","volume":"542","author":"Bardi","year":"2003","journal-title":"FEBS Lett"},{"key":"B22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.imlet.2012.05.002","article-title":"Involvement of the MAPK and RhoA\/ROCK pathways in PGE2-mediated CCR7-dependent monocyte migration","volume":"146","author":"Allaire","year":"2012","journal-title":"Immunol Lett"},{"key":"B23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/eji.201344429","article-title":"Fasudil mediates cell therapy of EAE by immunomodulating encephalomyelitic T cells and macrophages","volume":"45","author":"Liu","year":"2015","journal-title":"Eur J Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"6861","DOI":"10.1073\/pnas.89.15.6861","article-title":"Tissue- and site-specific DNA recombination in transgenic mice","volume":"89","author":"Orban","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/978-1-61779-442-1_11","article-title":"Rho GTPase knockout induction in primary keratinocytes from adult mice","volume":"827","author":"Pedersen","year":"2012","journal-title":"Methods Mol Biol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4776","DOI":"10.4049\/jimmunol.170.9.4776","article-title":"IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis","volume":"170","author":"Teige","year":"2003","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1091\/mbc.E09-10-0859","article-title":"RhoA is dispensable for skin development, but crucial for contraction and directed migration of keratinocytes","volume":"22","author":"Jackson","year":"2011","journal-title":"Mol Biol Cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4161\/sgtp.1.3.14724","article-title":"Multiple roles for RhoA during T cell transendothelial migration","volume":"1","author":"Heasman","year":"2010","journal-title":"Small GTPases"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ene.12798","article-title":"A basic overview of multiple sclerosis immunopathology","volume":"22","author":"Grigoriadis","year":"2015","journal-title":"Eur J Neurol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1021\/acs.jmedchem.5b00683","article-title":"Rho kinase (ROCK) inhibitors and their therapeutic potential","volume":"59","author":"Feng","year":"2016","journal-title":"J Med Chem"},{"key":"B32","doi-asserted-by":"publisher","first-page":"704","DOI":"10.2174\/156802609789044452","article-title":"Rho kinase (ROCK) inhibitors and their application to inflammatory disorders","volume":"9","author":"LoGrasso","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"B33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.cellbio.21.020604.150721","article-title":"Rho GTPases: biochemistry and biology","volume":"21","author":"Jaffe","year":"2005","journal-title":"Annu Rev Cell Dev Biol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/nature01148","article-title":"Rho GTPases in cell biology","volume":"420","author":"Etienne-Manneville","year":"2002","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"ra15","DOI":"10.1126\/scisignal.2000199","article-title":"Spatiotemporal patterning during T cell activation is highly diverse","volume":"2","author":"Singleton","year":"2009","journal-title":"Sci Signal"},{"key":"B36","doi-asserted-by":"publisher","first-page":"5973","DOI":"10.4049\/jimmunol.1400839","article-title":"Gene targeting RhoA reveals its essential role in coordinating mitochondrial function and thymocyte development","volume":"193","author":"Zhang","year":"2014","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1084\/jem.194.7.903","article-title":"Analysis of thymocyte development reveals that the GTPase RhoA is a positive regulator of T cell receptor responses in vivo","volume":"194","author":"Corre","year":"2001","journal-title":"J Exp Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/icb.2017.27","article-title":"T-cell activation RhoGTPase-activating protein plays an important role in TH17-cell differentiation","volume":"95","author":"Tamehiro","year":"2017","journal-title":"Immunol Cell Biol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1172\/JCI67233","article-title":"2-Photon imaging of phagocyte-mediated T cell activation in the CNS","volume":"123","author":"Pesic","year":"2013","journal-title":"J Clin Invest"},{"key":"B40","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nrd2805","article-title":"Averting inflammation by targeting the cytokine environment","volume":"9","author":"Kopf","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"B41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jneuroim.2009.06.011","article-title":"Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis","volume":"216","author":"Haas","year":"2009","journal-title":"J Neuroimmunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/ana.21722","article-title":"New pieces in the puzzle: how does interferon-beta really work in multiple sclerosis?","volume":"65","author":"Mitsdoerffer","year":"2009","journal-title":"Ann Neurol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1056\/NEJMoa1501481","article-title":"Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis","volume":"373","author":"Kappos","year":"2015","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2017.06.005","article-title":"Targeting the GM-CSF receptor for the treatment of CNS autoimmunity","volume":"84","author":"Ifergan","year":"2017","journal-title":"J Autoimmun"},{"key":"B45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jns.2015.12.011","article-title":"Ingested (oral) anti-IL-12\/23 inhibits EAE","volume":"361","author":"Brod","year":"2016","journal-title":"J Neurol Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","article-title":"Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study","volume":"7","author":"Segal","year":"2008","journal-title":"Lancet Neurol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1002\/(SICI)1521-4141(199911)29:11<3609::AID-IMMU3609>3.0.CO;2-S","article-title":"Rho GTPases control migration and polarization of adhesion molecules and cytoskeletal ERM components in T lymphocytes","volume":"29","author":"del Pozo","year":"1999","journal-title":"Eur J Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1111\/bph.12658","article-title":"Targeting Rho-GTPases in immune cell migration and inflammation","volume":"171","author":"Biro","year":"2014","journal-title":"Br J Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40265-013-0030-6","article-title":"Drugs in development for relapsing multiple sclerosis","volume":"73","author":"Ali","year":"2013","journal-title":"Drugs"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01235\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T00:31:09Z","timestamp":1527726669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01235\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,31]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2018.01235"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.01235","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,31]]},"article-number":"1235"}}